NATCO Pharma Limited (NSE: NATCOPHARM)
India
· Delayed Price · Currency is INR 1,437.50
-36.80 (-2.50%)
Oct 10, 2024, 3:30 PM IST
NATCO Pharma Revenue
NATCO Pharma had revenue of 13.63B INR in the quarter ending June 30, 2024, with 19.47% growth. This brings the company's revenue in the last twelve months to 43.49B, up 46.78% year-over-year. In the fiscal year ending March 31, 2024, NATCO Pharma had annual revenue of 40.02B with 47.76% growth.
Revenue (ttm)
43.49B
Revenue Growth
+46.78%
P/S Ratio
5.92
Revenue / Employee
10.83M
Employees
4,016
Market Cap
257.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 40.02B | 12.94B | 47.76% |
| Mar 31, 2023 | 27.09B | 7.62B | 39.17% |
| Mar 31, 2022 | 19.46B | -1.10B | -5.35% |
| Mar 31, 2021 | 20.56B | 1.41B | 7.37% |
| Mar 31, 2020 | 19.15B | -1.80B | -8.57% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNATCO Pharma News
- 3 days ago - Pharma Stocks Update: Natco Pharma gains 2.99%, Glenmark rises 0.07%, Granules falls 3.83% - Business Upturn
- 3 days ago - NATCO Pharma shares surge 3% after announcing settlement in U.S. patent litigation - Business Upturn
- 3 days ago - NATCO Pharma announces settlement in U.S. patent litigation for generic Ozempic - Business Upturn
- 5 weeks ago - Natco Pharma stock surges over 4% after submitting FDA application for lung cancer treatment - Business Upturn
- 6 weeks ago - Natco Pharma submits ANDA for generic version of Tabrecta, a $126M US market drug - Business Upturn
- 2 months ago - Q1 2025 Natco Pharma Ltd Earnings Call Transcript - GuruFocus